A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
APPRECIATE
APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
1 other identifier
observational
610
10 countries
133
Brief Summary
This is a retrospective, multi-center observational cohort study. This study will be implemented first in Germany (approximately 50 sites), the United Kingdom (approximately 20 sites) and Sweden (approximately 25 sites), followed by a selected number of countries in Europe, depending on apremilast local availability. The design of this apremilast retrospective study aims to provide clinical information regarding the treatment initiation and outcomes in psoriasis patients when prescribed apremilast in real world settings. In addition, this study is aiming at capturing physicians' and patients' treatment goals when initiating apremilast and whether these goals are achieved following apremilast use. This study is primarily descriptive in nature, and no a priori hypotheses are specified. Patients must voluntarily sign an informed consent form, be 18 or over, have been diagnosed with plaque psoriasis and have been treated with apremilast during the previous 5-7 months to participate in this study. They must not be involved in any other clinical study involving apremilast.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2016
Longer than P75 for all trials
133 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 12, 2016
CompletedFirst Posted
Study publicly available on registry
April 15, 2016
CompletedStudy Start
First participant enrolled
June 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 27, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 27, 2021
CompletedMarch 4, 2024
March 1, 2024
5.3 years
April 12, 2016
March 1, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Patient Benefit Index (PBI) outcome score
Is a questionnaire regarding patient expectations and benefit of psoriasis treatment with apremilast, eg, effect on specific symptoms.
Up to approximately 7 months
Secondary Outcomes (10)
Treatment Satisfaction Questionnaire for Medication (TSQM) outcome score
Up to approximately 7 months
Percentage of patients achieving PASI75
Up to approximately 7 months
Percentages of patients achieving PASI50
Up to approximately 7 months
Mean change in Dermatology Life Quality Index (DLQI)
Up to approximately 7 months
Percentages of patients achieving ≥5 point improvement in DLQI
Up to approximately 7 months
- +5 more secondary outcomes
Study Arms (1)
Psoriasis patients
Single cohort of psoriasis patients treated with OTEZLA (apremilast)
Interventions
Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
Eligibility Criteria
Patient charts will be selected for data abstraction by participating dermatologists and will be determined eligible for study enrollment based on the inclusion criteria. All consecutive adult psoriasis patients who can be contacted 6 months (+/- 1 month) following initiation of treatment with apremilast will be approached for entry to minimize bias in patient selection. All eligible patients will be included in consecutive order regarding the date of the signed Informed Consent.
You may qualify if:
- Must have understood and voluntarily signed the Informed Consent Form (ICF).
- Age ≥ 18 years at the time of signing the ICF.
- Diagnosed with plaque psoriasis.
- Initiated treatment with apremilast 6 months (+/- 1 month) previously (patients may or may not have completed 6 months of apremilast treatment)
You may not qualify if:
- Refusal to participate in this study or current participation in the treatment phase of an interventional clinical trial.
- Started apremilast as part of a clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Amgenlead
Study Sites (133)
Medizinische Universität Graz
Graz, 8036, Austria
Praxis Dr. Wolfgang Fuchs
Grosswarasdorf, 7304, Austria
Praxis Dr. Schicher
Klagenfurt, 9020, Austria
Praxis Dr. Wilhelm
Landeck, 6500, Austria
Kepler Universitätsklinikum
Linz, 4021, Austria
Praxis Dr. Dunst-Huemer
Linz, 4040, Austria
Krankenanstalt Rudolfstiftung
Vienna, 1030, Austria
Medizinische Universität Wien
Vienna, 1090, Austria
Praxis Dr. Göttfried
Vienna, 1100, Austria
Praxis Dr. Holub-Hoberger
Vienna, 1100, Austria
Krankenhaus Hietzing
Vienna, 1130, Austria
Praxis Dr. Nordberg
Vienna, 1170, Austria
Praxis Dr. Menzinger
Vienna, 1190, Austria
Praxis Dr. Sator
Vienna, 1190, Austria
Praxis Dr. Perl-Convalexius
Vienna, 1200, Austria
Klinikum Wels-Grieskirchen GmbH
Wels, 4600, Austria
Landesklinikum Wiener Neustadt
Wiener Neustadt, 2700, Austria
Klinički bolnički centar Osijek Zavod za dermatologiju i venerologiju
Osijek, 31 000, Croatia
Klinički bolnički centar Rijeka Klinika za dermatovenerologiju
Rijeka, 51000, Croatia
Klinički bolnički centar Split Klinika za kožne i spolne bolesti
Split, 21 000, Croatia
Klinički bolnički centar Sestre milosrdnice Klinika za kožne i spolne bolest
Zagreb, 10 000, Croatia
Klinički bolnički centar Zagreb Klinika za dermatovenerologiju
Zagreb, 10 000, Croatia
Fakultní nemocnice Hradec Králové Klinika nemocí kožních a pohlavních
Hradec Králové, Novy Hradec Králové, 500 05, Czechia
Nemocnice Pardubického kraje
Pardubice, Pardubice IV, 530 03, Czechia
Sanatorium profesora Arenberger
Prague, Praha 1, 110 00, Czechia
Všeobecná fakultní nemocnice v Praze
Prague, Praha 2, 128 08, Czechia
Fakultní nemocnice v Motole
Prague, Praha 5, 150 06, Czechia
Nemocnice Jihlava příspěvková organizace
Jihlava, 586 33, Czechia
FN Plzen Bory Dermatovenerologické oddělení
Pilsen, 301 00, Czechia
Company for Medical Study & Service
Selters, Westerwald, 56242, Germany
Praxis Dr. Harst
Aachen, 52062, Germany
Praxis Dr. Wagner-Schiffler
Aachen, 52066, Germany
Praxis Dr. Dietz
Ampfing, 84539, Germany
Praxis Dr. Bell
Andernach, 56626, Germany
Licca Clinical Research Institute
Augsburg, 86179, Germany
Gefäß- und Hautzentrum Blaustein
Blaustein, 89134, Germany
St. Josef und St. Elisabeth Hospital gGmbH
Bochum, 44791, Germany
Rheinische Friedrich-Wilhelms-Universität Bonn
Bonn, 53127, Germany
Praxis Dr. Jordan
Brühl, 50321, Germany
Elbe Klinikum Buxtehude
Buxtehude, 21614, Germany
Praxis Dr. Schneider
Dachau, 85221, Germany
Praxis Dr. Thelen
Delmenhorst, 27753, Germany
Klinikum Dortmund
Dortmund, 44137, Germany
Praxis Dr. Scheibner
Dresden, 01217, Germany
Praxis Dr. Korge
Düren, 52349, Germany
Praxis für Dermatologie und Venerologie, Allergologie
Eltville, 65343, Germany
Praxis Dr. Schurhammer-Fuhrmann
Endingen, 79346, Germany
Uniklinikum Erlangen
Erlangen, 91054, Germany
Praxis Dr. Huerkamp
Euskirchen, 53879, Germany
Praxis Dr. Swirski
Euskirchen, 53879, Germany
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany
Praxis Dr. Kämmerer
Freiberg, 09599, Germany
Praxis Dr. Kurzen
Freising, 85354, Germany
GP Dr. Rotterdam & Kollegen
Gelsenkirchen, 45883, Germany
Praxis Dr. med W. Klövekorn, Dr. med. A. Tepe, Dr. med. O. Wilde
Gilching, 82205, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
Praxis Dr. Schmidt
Kusel, 66869, Germany
Praxis Birgit Zimmermann
Malchow, 17231, Germany
Praxis Dr. Piontek
Mechernich, 53894, Germany
Dermatologische Praxis Dr. med. Schwinn
Memmingen, 87700, Germany
Praxis Büchler
Memmingen, 87700, Germany
Praxis Dr. Antal
Mühldorf, 84453, Germany
Praxis Dr. Cords
Mühlheim, 56218, Germany
Praxis Dr. Liebich
München, 80331, Germany
Technische Universität München
München, 80802, Germany
Universitätsklinikum Regensburg
Regensburg, 93053, Germany
Praxis Dr. Prell
Rosenheim, 83022, Germany
Praxis Dr. Blank
Rostock, 18055, Germany
Praxis Dr. Hoene
Rostock, 18059, Germany
Praxis Dr. Schenkelberger
Sankt Ingbert, 66386, Germany
Praxis Dr. Neisius
Stolberg, 52222, Germany
Praxis Dr. Steinborn
Straubing, 94315, Germany
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
Gemeinschaftspraxis Dr. Christian Fischer, Florian Kreuziger
Vilshofen, 94474, Germany
Praxis Dr. Dehmel
Wasserburg am Inn, 83512, Germany
Praxis Dr. Schmeel
Wesseling, 50389, Germany
Praxis Dr. Buttgereit
Wildau, 15745, Germany
Praxis Dr. Süß
Wittlich, 54516, Germany
Bon Secours Hospital
Tralee, County Kerry, Ireland
Mater Misericordiae University Hospital
Dublin, Ireland
University Hospital Galway
Galway, H91 YR71, Ireland
Uniiverzitetni klinični center Maribor Oddelek za kožne in spolne bolezni
Maribor, 2000, Slovenia
Hospital Fundacion Alcorcon, Madrid
Alcorcón, Madrid, 28922, Spain
Vithas Xanit Iinternational Hospital
Benalmádena, 29631, Spain
Hospital Universitario San Cecilio (PTS)
Granada, 18016, Spain
Hospital Virgen de la Victoria
Málaga, 29010, Spain
Hudkliniken Mälarsjukhuset
Eskilstuna, 631 88, Sweden
Hudkliniken SU/ Sahlgrenska
Gothenburg, 413 45, Sweden
Hudmottagningen Karlskoga Lasarett
Karlskoga, 69181, Sweden
Hudmottagningen Lindesbergs Lasarett
Lindesberg, 711 35, Sweden
Capio Citykliniken Lund
Lund, 222 21, Sweden
Diagnostiskt Centrum Hud Malmö
Malmo, 211 18, Sweden
SUS Malmö Hudkliniken
Malmo, 214 28, Sweden
Hudkliniken Vrinnevisjukhuset Norrköping
Norrköping, 601 82, Sweden
Diagnostiskt Centrum Hud Stockholm
Stockholm, 111 37, Sweden
Cutisgruppen/Stockholm Hud
Stockholm, 113 22, Sweden
Hudkliniken SÖS
Stockholm, 118 83, Sweden
Hudcentrum Hagastaden
Stockholm, 133 30, Sweden
Karolinska Psoriasis Center
Stockholm, 17176, Sweden
Hudkliniken Danderyds Sjukhus
Stockholm, 182 88, Sweden
Hudmottagningen Trelleborg
Trelleborg, 231 85, Sweden
Hudmottagningen Västervik
Västervik, 593 33, Sweden
Dermatologie Aesche
Basel, 4051, Switzerland
Somamedica
Basel, 4052, Switzerland
Ospedale Bellinzona e Valli EOC
Bellinzona, 6500, Switzerland
Insel Gruppe AG
Bern, 3010, Switzerland
Clinique dermatologie du Seujet
Geneva, 1201, Switzerland
Hautarzt Oberaargau AG
Herzogenbuchsee, 3360, Switzerland
Centre hospitalier universitaire Vaudois (CHUV)
Lausanne, 1011, Switzerland
Studio medico Dr. Pelloni
Lugano, 6900, Switzerland
Practice Dr. Niklaus
Martigny-Ville, 1920, Switzerland
Pallas Klinik Olten
Olten, 4600, Switzerland
Haut und Laserzentrum Dr. Zuder
Sankt Gallen, 9000, Switzerland
Praxis Dr. med. Christian Schuster
Sankt Gallen, 9000, Switzerland
Haut und Allergiezentrum Brunnehof
Uster, 8610, Switzerland
Dr. Tomi Haut- und Laserzentrum
Weinfelden, 8570, Switzerland
Hautpraxis Dermateam
Winterthur, 8400, Switzerland
Praxisgemeinschaft Bünz AG
Wohlen, 5610, Switzerland
Zug Hautarzt
Zug, 6300, Switzerland
Universitätsspital Zürich
Zurich, 8091, Switzerland
Aberdeen Royal Infirmary
Aberdeen, AB25 2ZB, United Kingdom
Bradford Teaching Hospitals NHS
Bradford, BD9 6RJ, United Kingdom
West Suffolk NHS Foundation
Bury St Edmunds, IP33 2QZ, United Kingdom
East Kent & Canterbury Hospital
Canterbury, CT1 3NG, United Kingdom
NHS Dumfries and Galloway
Dumfries, DG1 4AP, United Kingdom
Royal Devon & Exeter NHS Foundation Trust
Exeter, EX2 5DW, United Kingdom
West Middlesex University Hospital
Isleworth, TW7 6AF, United Kingdom
Chapel Allerton Hospital
Leeds, LS9 7TF, United Kingdom
Guy's and St Thomas's NHS Foundation Trust
London, SE1 9RT, United Kingdom
Chelsea & Westminster NHS Foundation Trust
London, SW10 9NH, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, NE7 7DN, United Kingdom
University of Manchester
Salford, M6 8HD, United Kingdom
Warwick Hospital
Warwick, CV34 5BW, United Kingdom
Related Publications (4)
Pedro Herranza, Lidia Trasobaresb, Almudena Mateuc, Esperanza Martínezd, Ricardo Ruiz-Villaverdee, Ofelia Baniandrésf, Javier Mataixg, Natalia Jiménez-Gómezh, Marta Serrai, Diana Patricia Ruiz Genaoj, Noelia Riverak, Jesús Tercedor-Sánchezl, Carmen Garciam, Myriam Cordeyn, Enrique Herrera-Acostao. Characterization and outcomes of patients treated with apremilast in the Spanish routine clinical practice: Results from the APPRECIATE study. Actas Dermosifiliogr.
BACKGROUNDCetkovska P, Dediol I, Sola M, Kojanova M, Trcko K, Carija A, Ceovic R, Ledic-Drvar D, Kastelan M, Hrabar A, Missoup MC, Mamun K. Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe. Adv Ther. 2023 Apr;40(4):1787-1802. doi: 10.1007/s12325-023-02468-3. Epub 2023 Mar 2.
PMID: 36862361BACKGROUNDda Silva Burger N, Tran KV, Typou M, Sommer R, Neasham D, Cordey M, Augustin M. Benefits and Satisfaction with Apremilast Treatment in Patients with Psoriasis Affecting the Genital Area: Secondary Analysis of the APPRECIATE Study. Dermatol Ther (Heidelb). 2025 Mar;15(3):681-695. doi: 10.1007/s13555-025-01360-y. Epub 2025 Feb 19.
PMID: 39969771DERIVEDJonak C, Gottfried I, Perl-Convalexius S, Gruber B, Schutz-Bergmayr M, Vujic I, Weger W, Schicher N, Semlin L, Hemetsberger M, Cordey M, Sator P. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study. Ther Adv Chronic Dis. 2023 Feb 7;14:20406223231152785. doi: 10.1177/20406223231152785. eCollection 2023.
PMID: 36777399DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
MD
Amgen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 12, 2016
First Posted
April 15, 2016
Study Start
June 30, 2016
Primary Completion
October 27, 2021
Study Completion
October 27, 2021
Last Updated
March 4, 2024
Record last verified: 2024-03